Table 1 Patient demographic and baseline characteristics

Age, years

 Median(range)

61(44–77)

 ≥ 65

28(37.8)

Sex

 Male/Female

44/30(59.5/40.5)

Ethnicities

 Han

71(96.0)

 Others

3 (4.0)

Median time (range) from initial diagnosis, years

3.4(2.2–6.2)

ECOG PS score

 0–1

66(89.2)

 2

8(10.8)

R-ISS stage

 I

19(25.7)

 II

42(56.8)

 III

13(17.6)

Renal insufficiency

(30 mL/min ≤ creatinine clearance < 60 mL/min), n(%)

 Yes

23(31.1)

Cytogenetic risk

 Standard

49 (66.2)

 High risk^b

25(33.8)

No. of prior lines, median(range)

3(1–9)

ASCT, n(%)

 Yes

8(10.8)

Prior MM therapy

 Yes

74(100.0)

 Bortezomib

74(100.0)

 Lenalidomide

74(100.0)

Refractory to^c

 Lenalidomide

55(74.3)

 Bortezomib

39(52.7)

 Bortezomib + Lenalidomide

32(43.2)